Back to Search
Start Over
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
- Source :
- International Journal of Cancer; Jul2012, Vol. 131 Issue 1, p140-149, 10p
- Publication Year :
- 2012
-
Abstract
- CD4<superscript>+</superscript> T cells have been shown to be crucial for the induction and maintenance of cytotoxic T cell responses and to be also capable of mediating direct tumor rejection. Therefore, the anticancer therapeutic efficacy of peptide-based vaccines may be improved by addition of HLA class II epitopes to stimulate T helper cells. Survivin is an apoptosis inhibiting protein frequently overexpressed in tumors. Here we describe the first immunological evaluation of a survivin-derived CD4<superscript>+</superscript> T cell epitope in a multipeptide immunotherapy trial for prostate carcinoma patients. The survivin peptide is promiscuously presented by several human HLA-DRB1 molecules and, most importantly, is naturally processed by dendritic cells. In vaccinated patients, it was able to induce frequent, robust and multifunctional CD4<superscript>+</superscript> T cell responses, as monitored by IFN-γ ELISPOT and intracellular cytokine staining. Thus, this HLA-DR restricted epitope is broadly immunogenic and should be valuable for stimulating T helper cells in patients suffering from a wide range of tumors. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00207136
- Volume :
- 131
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- International Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 74436955
- Full Text :
- https://doi.org/10.1002/ijc.26365